Efanesoctocog alfa

艾凡凝血素Ⅷ-α

Report date: 2026/04/21 20:00:18
First In Class

Base Information

Drug NameEfanesoctocog alfa
Drug Alias NameXTENylated Factor VIII凝血因子VIIIrFVIIIFc-VWF-XTENrFVIIIFc-XTEN-vWFEfanesoctocog +[14] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionCoagulation factor VIII replacements
TargetsCoagulation factor VIII
Therapy Area/Indicationsvon Willebrand DiseasesHemophilia A
Global Approved IndicationsHemophilia A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/02/23
Country/TerritoryCzechiaBelgiumBulgaria +[30] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAmunix Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSwedish Orphan Biovitrum AgBioverativ, A Sanofi CompanySwedish Orphan Biovitrum (Sobi) +[9] 
Inactive CompaniesN/A
Active Indicationsvon Willebrand DiseasesHemophilia A
Inactive IndicationsN/A

Other Information

ATC CodeB02BD02
Related LinksWikipediaDrugBankKEGG